Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAP-CAP Japan: Adaptive Platform Trial for Severe Community-Acquired Pneumonia and COVID-19
jRCT1031210150Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2021
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Randomised trial of ceftriaxone, levofloxacin and piperacillin + tazobactam in community-acquired pneumonia (CAP), coronavirus disease 2019 (COVID-19), acute respiratory decompensation and 1 more (10 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: All-cause mortality at Day 90. Started Jun 2021; status: recruiting.
02
Drugs
ceftriaxonelevofloxacinpiperacillin + tazobactam
03
Conditions
community-acquired pneumonia (CAP)coronavirus disease 2019 (COVID-19)acute respiratory decompensationsepsis
Beyond the preview
Go deeper on jRCT1031210150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210150.